Chorom Pak, CEO/Founder
Professional Overview
Chorom Pak is a seasoned bioscience leader with a proven track record of driving innovation and growth in the pharmaceutical industry. As the CEO and Founder of Lynx Biosciences (LynxBio), she is responsible for spearheading the company's strategic vision, overseeing research and development efforts, and fostering collaborative partnerships to advance novel drug candidates.
Experience Summary
Current Role
As the CEO and Founder of Lynx Biosciences, Chorom leads a talented team of researchers and clinicians dedicated to developing groundbreaking therapies for complex diseases. Under her guidance, the company has secured significant funding and established key industry partnerships to accelerate the development of its pipeline. Chorom's deep expertise in biologic drug development and her ability to navigate the regulatory landscape have been instrumental in positioning LynxBio as a leader in the field.
Career Progression
Prior to founding LynxBio, Chorom held various research and development roles, including serving as the Research and Clinical Development Lead at Cellectar Biosciences, Inc. and as a Biologist at the same organization. She also gained valuable experience as a Post-Doctoral Associate at the University of Wisconsin-Madison, where she conducted groundbreaking research and contributed to several high-impact publications.
Academic Background
Chorom holds a Ph.D. in Molecular Biology from the University of Wisconsin-Madison, where she specialized in oncology and immunology research. Her academic achievements include numerous peer-reviewed journal publications and prestigious research grants, showcasing her deep technical expertise and innovative problem-solving abilities.
Areas of Expertise
Chorom's areas of expertise span biologic drug development, clinical trial design, regulatory strategy, and effective team leadership. She is adept at navigating the complex pharmaceutical landscape, identifying emerging trends, and translating scientific insights into viable commercial opportunities. Chorom's ability to foster collaboration and drive cross-functional teams has been instrumental in advancing LynxBio's pipeline.
Professional Impact
Under Chorom's leadership, LynxBio has rapidly grown into a prominent player in the bioscience industry, garnering recognition for its innovative approaches and promising drug candidates. The company has secured significant funding, forged strategic partnerships, and made notable advancements in the clinical development of its pipeline. Chorom's commitment to scientific excellence and her proven ability to execute on ambitious goals have positioned LynxBio as a company to watch in the biopharmaceutical space.
Conclusion
With her extensive expertise, visionary leadership, and demonstrated success in bioscience innovation, Chorom Pak is poised to continue driving meaningful progress in the treatment of complex diseases. As the CEO and Founder of Lynx Biosciences, she is dedicated to leveraging the power of cutting-edge science to improve patient outcomes and make a lasting impact on the healthcare industry.
